7OT6 image
Entry Detail
PDB ID:
7OT6
Keywords:
Title:
HIV-1 REVERSE TRANSCRIPTASE COMPLEX WITH DNA AND inhibitor RMC-282
Biological Source:
PDB Version:
Deposition Date:
2021-06-09
Release Date:
2021-12-08
Method Details:
Experimental Method:
Resolution:
3.20 Å
R-Value Free:
0.25
R-Value Work:
0.22
R-Value Observed:
0.22
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Reverse transcriptase/ribonuclease H
Chain IDs:A (auth: C), C (auth: A)
Chain Length:556
Number of Molecules:2
Biological Source:Human immunodeficiency virus type 1 group M subtype B (isolate BH10)
Polymer Type:polypeptide(L)
Description:Reverse transcriptase/ribonuclease H
Chain IDs:B (auth: D), D (auth: B)
Chain Length:428
Number of Molecules:2
Biological Source:Human immunodeficiency virus type 1 group M subtype B (isolate BH10)
Polymer Type:polydeoxyribonucleotide
Description:DNA (5'-D(*AP*TP*GP*GP*AP*AP*GP*GP*CP*GP*CP*CP*CP*GP*AP*AP*CP*AP*GP*GP*GP*AP*CP*TP*GP*TP*G)-3')
Chain IDs:E, H (auth: T)
Chain Length:27
Number of Molecules:2
Biological Source:Human immunodeficiency virus type 1 BH10
Polymer Type:polydeoxyribonucleotide
Description:DNA (5'-D(*CP*AP*GP*TP*CP*CP*CP*TP*GP*TP*TP*CP*GP*GP*(MRG)*CP*GP*CP*CP*(DDG))-3')
Chain IDs:F, G (auth: P)
Chain Length:20
Number of Molecules:2
Biological Source:Homo sapiens
Primary Citation
Exploring the dNTP -binding site of HIV-1 reverse transcriptase for inhibitor design.
Eur.J.Med.Chem. 225 113785 113785 (2021)
PMID: 34425311 DOI: 10.1016/j.ejmech.2021.113785

Abstact

HIV-1 reverse transcriptase (RT) plays a central role in the viral life cycle, and roughly half of the FDA-approved anti-HIV drugs are targeting RT. Nucleoside analogs (NRTIs) require cellular phosphorylation for binding to RT, and to bypass this rate-limiting path, we designed a new series of acyclic nucleoside phosphonate analogs as nucleoside triphosphate mimics, aiming at the chelation of the catalytic Mg2+ ions via a phosphonate and/or a carboxylic acid group. Novel synthetic procedures were developed to access these nucleoside phosphonate analogs. X-ray structures in complex with HIV-1 RT/dsDNA demonstrated that their binding modes are distinct from that of our previously reported compound series. The impact of chain length, chirality and linker atom have been discussed. The detailed structural understanding of these new compounds provides opportunities for designing new class of HIV-1 RT inhibitors.

Legend

Protein

Chemical

Disease

Primary Citation of related structures